GLP-1/glucagon dual receptor agonist ALT-801 is superior to semaglutide in improving NASH endpoints in a biopsy-confirmed DIO mouse model

被引：0
|
作者：
Nestor, John [1 ]
Rigbolt, Kristoffer [2 ]
Feigh, Michael [2 ]
Parkes, David [3 ]
Harris, M. Scott [1 ]
机构：
[1] Altimmune Inc, Gaithersburg, MD USA
[2] Gubra, Horsholm, Denmark
[3] DGP Sci, Del Mar, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI117
引用
收藏
页码：S456 / S456
页数：1
相关论文
共 45 条
  • [41] YH25724, a novel long-acting GLP-1/FGF21 dual agonist lowers both non-alcoholic fatty liver disease activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis
    Hong, H. N.
    Kim, J. H.
    Choi, H. H.
    Kim, D.
    Kim, T. W.
    Tolbol, K. S.
    Feigh, M.
    Illemann, M.
    Rigbolt, K.
    Vrang, N.
    Kim, J. G.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S16 - S17
  • [42] Correction to: Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
    Matthias Blüher
    Julio Rosenstock
    Josef Hoefler
    Raymond Manuel
    Anita M. Hennige
    Diabetologia, 2024, 67 : 758 - 758
  • [43] Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
    Blueher, Matthias
    Rosenstock, Julio
    Hoefler, Josef
    Manuel, Raymond
    Hennige, Anita M.
    DIABETOLOGIA, 2024, 67 (03) : 470 - 482
  • [44] The FXR/TGR5 Dual Agonist INT-767 Reduces NAFLD Activity Score and Fibrosis Stage and Improves Plasma and Hepatic Lipid Profiles in the GUBRA-AMLN Mouse Model of Diet-induced and Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
    Roth, Jonathan
    Feigh, Michael
    Veidal, Sanne Skovgaard
    Rigbolt, Kristoffer
    Jelsing, Jacob
    Vrang, Niels
    Young, Mark
    HEPATOLOGY, 2016, 64 : 752A - 753A
  • [45] Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial (vol 67, pg 470, 2024)
    Blueher, Matthias
    Rosenstock, Julio
    Hoefler, Josef
    Manuel, Raymond
    Hennige, Anita M.
    DIABETOLOGIA, 2024, 67 (04) : 758 - 758
12345